Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab
Status:
Not yet recruiting
Trial end date:
2025-11-20
Target enrollment:
Participant gender:
Summary
This is an open label phase 2 clinical trial evaluating the clinical safety, feasibility and
efficacy of neoadjuvant Adagrasib alone or in combination with nivolumab in patients with
NSCLC with KRAS G12C mutation.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins